Clinical trial
Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
NCT00159445 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00159445 |
|---|---|
| Title | Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer |
| Official title | Phase II Study of Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Colon Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, capecitabine |
| Enrollment | 53 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: